← All trials
NCT00395174
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2006
- Primary completion
- May 1, 2007
- Completion date
- May 1, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 870
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Protein Sciences CorpLead sponsor
- Baylor UniversityOverall official - principal investigator
- Mayo ClinicOverall official - principal investigator
- University of MarylandOverall official - principal investigator
- University of RochesterOverall official - principal investigator
- Passport HealthOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.